We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$45.3M
AUM Growth
-$15.1M
Cap. Flow
-$15.4M
Cap. Flow %
-34.05%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$112K

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$15.3M
2
CDTX
Cidara Therapeutics
CDTX
+$218K

Sector Composition

Rank Sector Weight
1 Healthcare 42.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$26M 57.34%
1,240,000
-750,000
-38% -$15.3M
ADMA icon
2
ADMA Biologics
ADMA
$2.03B
$16.1M 35.46%
3,608,171
– –
CDTX
3
DELISTED
Cidara Therapeutics
CDTX
$1.78M 3.93%
44,581
-6,476
-13% -$218K
ASXC
4
DELISTED
Asensus Surgical, Inc.
ASXC
$1.48M 3.27%
183,796
– –
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
$0 ﹤0.01%
+18,964
New +$112K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Aisling Capital held 5 positions worth $45.3M, down 25% from $60.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital withdrew a net $15.4M in Q3 2019, reducing 2 holdings. Its largest reduction was Aimmune Therapeutics, cutting an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 31% a quarter earlier.

Against the trend, Aisling Capital opened a new position in ViewRay, Inc. worth $0.

  • Aisling Capital's largest Q3 2019 buy was ViewRay, Inc.: 18,964 shares worth $0.
  • Aisling Capital's biggest Q3 2019 reduction was Aimmune Therapeutics, cutting an estimated $15.3M.
  • Aisling Capital's ten largest holdings make up 100% of its $45.3M portfolio in Q3 2019.
  • Aisling Capital opened 1 new position and closed 0 in Q3 2019.
  • Aisling Capital's portfolio value fell 25% quarter-over-quarter to $45.3M.

Based on Aisling Capital's 13F filing for Q3 2019, filed 13 Nov 2019.